Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...

Editor's note: Details about rilzabrutinib have been corrected in this article. Sanofi's rilzabrutinib performed well in its phase 3 clinical trial, meaning the company can now apply for approval.

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...

Sanofi SNY announced positive data from the phase III LUNA 3 study, which evaluated its covalent BTK inhibitor, rilzabrutinib, for treating patients with immune thrombocytopenia (ITP), an ...

Researchers conducted a phase 1/phase 2 open-label study to evaluate the efficacy and safety of rilzabrutinib (Sanofi) — reversible Bruton tyrosine kinase inhibitor — among adults with ...

Rilzabrutinib is a promising treatment option for patients with chronic spontaneous urticaria who are refractory to antihistamines.

Rilzabrutinib (Sanofi) also significantly improved overall response rate and quality-of-life measures compared with placebo, findings presented at ASH Annual Meeting and Exposition showed.

The FDA granted Sanofi (SNY) US Services’ rilzabrutinib orphan designation as a treatment of immunoglobulin G4-related disease, according to a post to the agency’s website. Don't Miss Our End ...

Rilzabrutinib, an oral inhibitor of Bruton ... This work was supported by Sanofi. Giménez-Arnau reported receiving grants and personal fees from various companies, including Novartis, and serving ...

Sanofi has presented promising results from a phase 3 study of its investigational oral Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib in patients with immune thrombocytopenia (ITP). Data from ...